A multicenter, randomized, open label, two treatment, twoperiod, two sequence, single-dose, two-way, crossover, bioequivalence study of Methotrexate Tablets USP, 2.5 mg manufactured by Amneal Pharmaceuticals, withMethotrexate Tablets USP 2.5 mg Manufactured for DAVAPharmaceuticals, Inc., Fort Lee, NJ 07024 USA in patientswith mild to severe psoriasis or rheumatoid arthritis, who are already on established regimens of 2.5 mg every 12 hours under fasting condition.

Amneal Pharmaceuticals USA0 个研究点目标入组 48 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 未知
状态: 招募中
发起方
入组人数: 48

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Ba/be

入排标准

入选标准

•1.Men or Women, between 18 to 65 years of age (both inclusive).
•2.Ability to provide informed consent prior to participation in the study
•3.Patients with mild to severe psoriasis or rheumatoid arthritis, who are already on established regimens of 2.5 mg every 12 hours (7.5 mg per week in three divided doses).
•4.Confirmed diagnosis of psoriasis by clinical examination or after dermatologic consultation.
•Confirmed diagnosis of mild to severe rheumatoid arthritis based on at least 1 of the following:
•i.Documented history of positive rheumatoid factor
•ii.Current presence of rheumatoid factor
•iii.Radiographic erosion within 12 months prior to enrollment
•iv.Presence of serum anti-cyclic citrullinated peptide antibodies (anti-CCP).
•5.Women of childbearing potential (except for those who have completed one year since menopause or have gone through hysterectomy or bilateral tubal ligation within past 6 months) must have a negative serum pregnancy test at screening and negative urine pregnancy test on check in to housing, and must agree to use an adequate method of contraception.
•6.Patientâ??s screening laboratory assessment (complete blood count [CBC] and blood chemistries) are clinically non-significant as per the discretion of the Investigator.
•7.No history of addiction to any recreational drug or drug dependence.
•8.No participation in any clinical study within the past 60 days prior to receiving the first dose of investigational product for the current study.

排除标准

•1.A history of allergic or adverse reactions to Methotrexate Sodium or any related drug or any excipient of methotrexate tablets.
•2.Male or female of childbearing potential unwilling to use barrier contraceptive precautions throughout the trial and at least for 3 months (for males) and for at least one ovulatory cycle (for females) after last dose of study medication.
•3.Patients with alcoholism, alcoholic liver disease or other chronic liver disease.
•4.Patients who are diagnosed to be HIV or Hepatitis B or Hepatitis C Virus reactive/positive.
•5.Patients who have clinically significant abnormal laboratory values at screening.
•6.Patients with any evidence of organ dysfunction or any clinically significant deviation from normal in their physical or clinical evaluation including ECG and X-ray results except study indication.
•7.Patients who have overt or laboratory evidence of immunodeficiency syndromes.
•8.Patients currently suffering from or having a history of malignant lymphoma or tumor lysis syndrome.
•9.Patients who have pre-existing hematopoietic impairment/ blood dyscrasias, such as bone marrow hypoplasia, aplastic anemia, pancytopenia, leukopenia, neutropenia, thrombocytopenia and or significant anemia.
•10.Patient with lymphadenopathy and lymphoproliferative disorders.

研究者

发起方

Amneal Pharmaceuticals USA

相似试验

暂停

不适用

Bioequivalence study of Paliperidone Palmitate in schizophrenia patients

CTRI/2019/02/017754Amneal Pharmaceuticals Company GmbH

尚未招募

Unknown

This is a drug concentration assessment study of Azacitidine 300 mg tablets in patients with Blood Cancer (Acute Myeloid Leukemia).

CTRI/2024/03/064636PLIVA Croatia Ltd

已完成

不适用

To compare bioavailibility of Methotrexate Tablets 2.5 mg( Actavis LLC) with Methotrexate Tablets USP 2.5 mg (DAVA Pharmaceuticals, Inc.USA) in patients with mild to severe psoriasis or rheumatoid arthritis, who are already on establishedregimens of 2.5 mg every 12 hours under fasting condition.

CTRI/2015/05/005737Actavis LLC42

已完成

不适用

Two treatment Bioequivalence study of Methotrexate 2.5 mg in patients with Rheumatoid Arthritis (RA).

CTRI/2022/09/045447Elite Pharmaceuticals48

招募中

不适用

This is a drug concentration assessment study of Azacitidine 300 mg tablets in patients with Blood Cancer (Acute Myeloid Leukemia).

CTRI/2022/03/040956Watson Pharma Pvt Ltd